Merck KGaA to acquire Silence Therapeutics for about 1.2 billion dollars, around 20 per ADS
FROM THE WIRE · FINANCE.YAHOO.COM
Silence Therapeutics has surged into the spotlight after a sharp re-rating of its share price and a takeover agreement, which puts fresh focus on a simple question for investors. With the stock now trading near the agreed acquisition level, the open issue is how well that price…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe offer sets a reference price for the stock, which already trades near the deal level after a sharp rally.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Merck KGaA plans to acquire Silence Therapeutics for roughly 1.2 billion dollars.
- 02The valuation is around 20 dollars per American depositary share.
- 03The stock has gained about 218% year to date.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Silence Therapeutics plc19.58 USDMarket closedtoday +125.58%Neutral Merck KGaA144.35 EURMarket closedtoday +0.03%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets